Abstract
Glucocorticoids (GCs) exert their effects through regulation of gene expression after activation in the cytoplasm of the glucocorticoid receptor (GR) encoded by NR3C1 gene. A negative feedback mechanism resulting in GR autoregulation has been demonstrated through the binding of the activated receptor to intragenic sequences called GRE-like elements, contained in GR gene.
The long noncoding RNA growth arrest–specific transcript 5 (GAS5) interacts with the activated GR suppressing its transcriptional activity. The aim of this study was to evaluate the possible role of GAS5 and NR3C1 gene expression in the antiproliferative effect of methylprednisolone in peripheral blood mononuclear cells and to correlate the expression with individual sensitivity to GCs. Subjects being poor responders to GCs presented higher levels of GAS5 and NR3C1 in comparison with good responders. We suggest that abnormal levels of GAS5 may alter GC effectiveness, probably interfering with the mechanism of GR autoregulation.
Keywords: GAS5, gene expression, glucocorticoid receptor, long noncoding RNA, methylprednisolone, NR3C1 gene, proliferation assay.
Current Molecular Medicine
Title:Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Volume: 15 Issue: 1
Author(s): M. Lucafo, S. De Iudicibus, A. Di Silvestre, M. Pelin, L. Candussio, S. Martelossi, A. Tommasini, E. Piscianz, A. Ventura and G. Decorti
Affiliation:
Keywords: GAS5, gene expression, glucocorticoid receptor, long noncoding RNA, methylprednisolone, NR3C1 gene, proliferation assay.
Abstract: Glucocorticoids (GCs) exert their effects through regulation of gene expression after activation in the cytoplasm of the glucocorticoid receptor (GR) encoded by NR3C1 gene. A negative feedback mechanism resulting in GR autoregulation has been demonstrated through the binding of the activated receptor to intragenic sequences called GRE-like elements, contained in GR gene.
The long noncoding RNA growth arrest–specific transcript 5 (GAS5) interacts with the activated GR suppressing its transcriptional activity. The aim of this study was to evaluate the possible role of GAS5 and NR3C1 gene expression in the antiproliferative effect of methylprednisolone in peripheral blood mononuclear cells and to correlate the expression with individual sensitivity to GCs. Subjects being poor responders to GCs presented higher levels of GAS5 and NR3C1 in comparison with good responders. We suggest that abnormal levels of GAS5 may alter GC effectiveness, probably interfering with the mechanism of GR autoregulation.
Export Options
About this article
Cite this article as:
Lucafo M., Iudicibus De S., Silvestre Di A., Pelin M., Candussio L., Martelossi S., Tommasini A., Piscianz E., Ventura A. and Decorti G., Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response, Current Molecular Medicine 2015; 15 (1) . https://dx.doi.org/10.2174/1566524015666150114122354
DOI https://dx.doi.org/10.2174/1566524015666150114122354 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Design, Synthesis and Anticancer Activity Against the MCF-7 Cell Line of Benzo-Fused 1,4-Dihetero Seven- and Six-Membered Tethered Pyrimidines and Purines
Current Medicinal Chemistry Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia
Recent Advances in Drug Delivery and Formulation Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry